Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- OXUR.BR
- Price
- 0.10
- Stock movement up
- +0.00 (1.11%)
- Company name
- Oxurion NV
- Exchange
- (BR ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 257.00K
- Ent value
- 19.50M
- Price/Sales
- 0.97
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -58.92%
- 1 year return
- -89.99%
- 3 year return
- -97.84%
- 5 year return
- -91.75%
- 10 year return
- -73.14%
Last updated: 2025-04-18
DIVIDENDS
OXUR.BR does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.97 |
| Price to Book | - |
| EV to Sales | 73.86 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 2.57M |
| EPS (TTM) | -17.92 |
| FCF per share (TTM) | -12.47 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 264.00K |
| Gross profit (TTM) | -69.00K |
| Operating income (TTM) | -15.25M |
| Net income (TTM) | -22.00M |
| EPS (TTM) | -17.92 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | -26.14% |
| Operating margin (TTM) | -5775.76% |
| Profit margin (TTM) | -8331.82% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 119.00K |
| Net receivables | 569.00K |
| Total current assets | 1.55M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 4.55M |
| Accounts payable | 5.51M |
| Short/Current long term debt | 11.91M |
| Total current liabilities | 19.32M |
| Total liabilities | 19.36M |
| Shareholder's equity | -14.81M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -15.20M |
| Capital expenditures (TTM) | 1.50K |
| Free cash flow (TTM) | -15.31M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -483.22% |
| Return on Invested Capital | 751.23% |
| Cash Return on Invested Capital | 522.75% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.10 |
| Daily high | 0.10 |
| Daily low | 0.10 |
| Daily Volume | 10K |
| All-time high | 471700.00 |
| 1y analyst estimate | 0.30 |
| Beta | 0.58 |
| EPS (TTM) | -17.92 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| OXUR.BR | S&P500 | |
| Current price drop from All-time high | -100.00% | -14.12% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 17 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -63.92% | -11.07% |
| Avg time to new high | 48 days | 12 days |
| Max time to new high | 3139 days | 1805 days |
COMPANY DETAILS
Marketcap
257.00K
Marketcap category
Small-cap
Description
Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness. It focuses on developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
Employees
20
Website
Investor relations
-
SEC filings
CEO
Country
Belgium
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Oxurion Share Consolidation Leuven, BELGIUM – July 25, 2024 – 06:00 PM CET Oxurion NV (Euronext Brussels: OXUR) (the Company), a biopharmaceutical company based in Leuven, announced today that its Boa...
July 25, 2024
Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024 Leuven, BELGIUM – 24 July, 2024 – 06.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company ...
July 24, 2024
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 1...
July 19, 2024
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – July 18, 2024 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headq...
July 18, 2024
Oxurion provides clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024 Leuven, BELGIUM – July 11, 2024 – 6:00pm CET – Oxurion NV (Euronext Brussels:...
July 11, 2024
Oxurion signs a Letter of Intent and enters into exclusive negotiations to potentially acquire a pioneering French CRO in stem cell production LEUVEN, BELGIUM - July 8, 2024 – 6:30 pm, Oxurion NV (Eur...
July 8, 2024
Oxurion announces the results of the Extraordinary General Meeting (EGM) held on 4 July 2024 and convenes a new EGM on 24 July 2024. Leuven, BELGIUM - 4 July 2024 – 6:00 PM CET, Oxurion NV (Euronext B...
July 4, 2024
Oxurion Announces Extraordinary General Shareholders’ Meeting Leuven, BELGIUM – June 4, 2024 – 07:00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven,...
June 4, 2024
Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024 Leuven, BELGIUM – 23 May, 2024 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquart...
May 23, 2024
` Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD Leuven, BELGIUM – May 6, 2024 – 6:00 PM CET, Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical ...
May 6, 2024